mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma

mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma

Abstract Sirolimus is a regularly applied immunosuppressant for patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). Sirolimus not only significantly inhibits HCC recurrence but also protects renal function. However, the improvement effect of sirolimus on nontumour-rela...

Full description

Bibliographic Details
Main Authors: Lincheng Zhang, Peng Liu, Li Zhuang, Sunbin Ling, Qifan Zhan, Wei Zhou, Renyi Su, Lu Yin, Qingyang Que, Jiachen Hong, Jiaqi Bao, Chuxiao Shao, Jinzhen Cai, Shusen Zheng, Xiao Xu
Format: Article
Language:English
Published: Springer 2024-03-01
Series:Molecular Biomedicine
Subjects:
Sirolimus
Liver transplantation
Hepatocellular carcinoma
Nontumour-related death
Online Access:https://doi.org/10.1186/s43556-024-00170-6

Internet

https://doi.org/10.1186/s43556-024-00170-6

Similar Items